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In vitro evaluation of PEGylated mesoporous MgFe2O4
magnetic nanoassemblies (MMNs) for chemo-thermal
therapy†
Sunil Kumar,a Amita Daverey,‡b Niroj Kumar Sahub and Dhirendra Bahadur*b
A size tunable synthesis of mesoporous MgFe2O4 magnetic nanoassemblies (MMNs) through a PEG-diacid
mediated polyol method is reported. The PEG-diacid coated MMNs exhibit a signiﬁcant speciﬁc surface
area of 92 m2 g1 and saturation magnetization of 57 emu g1. These MMNs exhibit a very good
colloidal stability in PBS (pH 7.4) with nonappreciable cytotoxicity in mouse ﬁbroblast (L929) and cervical
cancer (HeLa) cells. We demonstrate the potential of MMNs as an integrated nanosystem for drug
delivery and magnetic hyperthermia (MHT) through in vitro studies. 80% loading eﬃciency of
doxorubicin (DOX) has been achieved due to the highly negative surface charge and mesoporous
nature of MMNs. It is observed that 65–70% of HeLa cells undergo apoptosis through DNA
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fragmentation after 24 h of incubation with DOX loaded MMNs. MHT alone induces the death of 40–
45% of cells, whereas the synergistic eﬀect of a combination of DOX and MHT leads to the death of
about 90% of cells. Our results show that MHT signiﬁcantly increases the therapeutic eﬃcacy of DOX to
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induce more apoptosis in cancer cells. Hence, a combination of MHT with chemotherapy makes MMNs a
powerful multimodal system for synergistic chemo-thermal cancer therapy.

Introduction

Chemotherapy is the rst line therapy for the treatment of
cancer. But several disadvantages associated with this therapy
such as nonselective distribution of drugs, multidrug resistance, undesirable side eﬀects on normal tissue and other
physical inconveniences to the patients resulted in researchers
developing alternative approaches for the improved treatment
of cancer. Nano drug-delivery systems have been shown to
reduce some side eﬀects of chemotherapy associated with nonselective distribution and the toxic eﬀects of drugs.1,2 Besides
delivery of the drug to the tumour sites, advanced nanomaterials have been shown to open doors to dual-therapies.
Moving in this direction, nanomaterials having the functionalities of hyperthermia and chemotherapy in a single system
are more in demand for cancer treatment. Several studies have
shown that the therapeutic eﬃcacy of any anticancer drug such
as doxorubicin (DOX) can be enhanced by combination with
a
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hyperthermia.3,4 Diﬀerent nanostructures such as gold nano
shells,5 carbon nanotubes,6 graphene,7 and magnetic nanoparticles3,8 have been used extensively for the chemo-thermal
ablation of tumours. Among these, oxide magnetic nanoparticles (MNPs) have emerged as a better option due to their
good biocompatibility, degradability under mild acidic conditions, magnetic manipulation, magnetic resonance imaging
(MRI) properties and capability to generate controlled noninvasive heat under an alternating current (AC) magnetic eld
(AMF).8–10 MNPs have been used for several drug delivery
applications, but one of the limitations is their ability to carry a
large amount of anticancer drug at tumour sites. To enhance
the drug carrying capacity of MNPs, various nanohybrid drug
delivery carriers such as peptide mimic shell cross-linked
magnetic nanocarriers (PMNCs),11 magnetic liposomes,8 alginate embedded magnetic nanoheaters3 etc. have been developed. However, these nanohybrids also have problems such as
large size, complex design and non-reproducibility. Recently,
mesoporous12 and hollow nanoparticles13 have emerged as
promising candidates for dual therapy due to their capability
to hold a large amount of anticancer drug at the tumour site
and minimize systemic drug toxicity. These features of mesoporous nanoparticles are attributed to their large surface area
and pore volume.12 Previous studies have reported the
synthesis of water dispersible mesoporous magnetic nanoassemblies (MMNs) using polyacrylic acid,14 trisodium
citrate,15 and poly-g-glutamic acid12 as stabilizing agents.
However, these methods have their limitations with respect to
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biocompatibility or the large size of the magnetic nanoassemblies (>200 nm). Large nanoassemblies cannot be eﬃciently injected into the body intravenously as a drug carrier.
In addition, due to large size of the particles, they are easily
sequestered by the spleen and removed by the phagocyte
system of the body resulting in the reduction of blood circulation time.16,17 Therefore, new methods and suitable stabilizing agents are needed to synthesize ideal magnetic
nanoassemblies uniquely capable of drug delivery, imaging
and magnetic hyperthermia.
In the present work, we have prepared a novel, highly water
dispersible, biocompatible and size tunable (<100 nm) mesoporous MgFe2O4 magnetic nanoassemblies (MMNs) by a polyol
method using PEG-diacid as a stabilizing agent. The advantages of the synthesized MMNs over other nanoassemblies and
nanoparticles are (i) their size range lies between the renal
clearance threshold (8 nm) and the gap in leaky cancer blood
vessels (100 nm), which is good to exploit passive tumour
targeting through enhanced permeation and retention eﬀect
(EPR),16 (ii) PEG modication on the surface of the MMNs
helps in resisting the adsorption of unwanted plasma protein
and increases the colloidal stability for prolonged blood
circulation, and (iii) MMNs are more biocompatible due to the
presence of Mg2+ ions which are required for ATP hydrolysis
for energy generation, genomic stability and catalytic activity of
almost all enzymatic systems involved in DNA processing.18,19
The potential applications of these MMNs were evaluated for
DOX delivery and magnetic hyperthermia (Scheme 1). DOX was
loaded into mesoporous MMNs through electrostatic interaction, henceforth referred to in the text as DOX–MMNs. We
compared the combined eﬀect of chemotherapy and MHT with
individual treatments in human cervix adenocarcinoma HeLa
cells. Our results show the novelty and potential of DOX–
MMNs for synergistic combination therapy leading to
apoptosis through DNA fragmentation and cell membrane
distortion. The enhancement of the DOX eﬃcacy and the
synergistic eﬀect with MHT to induce more cell death make
MMNs a powerful nanosystem for chemo-thermal cancer
therapy.
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Experimental section

2.1

Reagents and materials

All the chemicals were of analytical grade and used as received.
Iron(III) chloride hexahydrate (FeCl3$6H2O, 99%), magnesium(II) chloride hexahydrate (MgCl2$6H2O, 99%), doxorubicin–
HCl salt (DOX, $98%), poly(ethylene glycol)bis(carboxy methyl)
ether (HOOC–PEG–COOH Mn 600), 3-(4,5-dimethyl-thiazol-2yl)2,5-diphenyl tetrazolium bromide (MTT, >98%), 4,6-diamidino2-phenylindole (DAPI, >98%), propidium iodide (PI, >94%),
ethidium bromide (EtBr, >95%), and rhodamine-6G (99%) and
phalloidin-tetramethyl rhodamine-B-isothiocyanate conjugates
were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (inner salts, MTS) and phenazine
methoxysulfonate were procured from Promega (PMS), Madison, USA. Sodium borohydride (NaBH4, Merck, 98%), sodium
acetate (CH3COONa, Aldrich, 99%) and ethylene glycol (EG,
Merck, 99.8%) were used in the reaction. Dulbecco's modied
eagle medium (DMEM), antibiotic and antimycotic solution
were obtained from Hi-Media Ltd (Mumbai, India) and L929
and HeLa cell lines were procured from the National Center of
Cell Science (NCCS, Pune, India). Milli-Q water (18.2 MU cm)
was used throughout the experiments.
2.2

In a typical synthesis procedure, FeCl3$6H2O (3.7 mM, 1 g) and
MgCl2$6H2O (1.9 mM, 0.38 g) in a molar ratio of 2 : 1, PEGdiacid (3.5 g, 600 g per mole), and sodium acetate (NaAc,
CH3COONa, 3 g) were dissolved in 15 mL of EG in a 100 mL
three neck round bottom ask. The mixture was heated to
180  C in an inert (N2 gas) environment for 30 min. A solution of
sodium borohydride (0.05 g in 10 mL of EG) was prepared and
injected into the reaction vessel at 180  C. It was then reuxed
for 8 h at 200  C. The solution was cooled down to room
temperature in an inert protected environment and the black
precipitates were obtained by repeatedly washing with ethanol
and Milli-Q water using a magnetic separation method.
2.3

Scheme 1 Schematic representation of carboxyl enriched PEGylated MMNs
synthesis and evaluation of their eﬃciency for chemo-thermal treatment against
cancer cells.
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Synthesis procedure for MMNs

Characterization techniques

The identication and purity of the phase were determined by
X-ray diﬀraction (XRD) using a Philips powder diﬀractometer
(PW3040/60) with Cu Ka radiation (l ¼ 1.5405 Å) and a Ni lter.
The average crystallite size was calculated using the Scherrer
relationship. Fourier transform infrared spectra of the dried
powder samples were recorded using an FTIR instrument
(Magna550, Nicolet Instruments Corporation, USA) using the
KBr pellet technique. Thermal analysis was carried out in a
thermo gravimetric–diﬀerential thermal analysis instrument
(SDT Q100, USA). The samples under examination were heated
from room temperature to 650  C at a rate of 10  C min1 in a
nitrogen atmosphere. The specic surface area, pore volume
and pore size distribution of the MMNs were measured using a
Micromeritics instrument (ASAP 2020). Prior to measurement,
the sample was degassed at 120  C for 6 h. The microstructure
and surface morphology of the samples were analysed using a
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transmission electron microscope (TEM, JEOL JEM-2100F) and
eld emission scanning electron microscope (FEGSEM, JEOL
JEM-7600F). The composition of the sample was determined by
the energy dispersive X-ray spectroscopy (EDX) technique.
Weight chemical analysis was performed using an inductively
coupled plasma-atomic emission spectrometer (ICP-AES,
ARCOS, and Germany). Magnetic properties of the samples were
measured in a Quantum design magnetic properties measurement system (PPMS).
2.4

In vitro DOX loading and release

DOX–MMN conjugates were prepared using electrostatic interactions between positively charged doxorubicin (DOX) and the
negatively charged MMNs. The maximum loading amount of
DOX into the pores of the MMNs was determined by the serial
addition of MMNs (10, 50, 100, 150, 200, and 300 mg mL1) to a
xed concentration of DOX solution (16 mg mL1 in 600 mL of
PBS, pH 7.4) and the uorescence was monitored at excitation
with 480 nm, and the emission was recorded in the range 500–
750 nm using a Hitachi F 2500 spectrouorometer. To examine
the loading eﬃciency, a standard curve was plotted with known
concentrations of DOX dissolved in PBS at pH 7.4. The amount
of DOX loaded (DLoaded) into the nanoparticles was calculated as
follows:
Dloaded ¼ Dtotal  Dsupernatant

(1)

where, Dtotal is the amount of drug added for loading and
Dsupernatant is the amount of drug calculated from the supernatant aer the settling of the MMNs by an external magnet.
Furthermore, the loading eﬃciency of DOX into the MMNs was
calculated using following equation:
% efficiency ¼

Dloaded
 100
Dtotal

(2)

The in vitro drug release prole of the DOX–MMNs was
determined by loading DOX–MMNs (5 mg) samples into a
dialysis bag (Himedia, dialysis membrane-150, LA401), which
was submerged in 5 mL of phosphate-buﬀered saline (PBS,
pH ¼ 7.4) and acetate buﬀer of pH 5.2 at 37  C. The dialysate
was taken out aer a specic time interval to estimate the
amount of drug released while the same amount of fresh buﬀer
of the respective pH was added and kept in the shaker for
further experimentation. The DOX concentration in the sample
was measured by uorescence intensity at lexcitation ¼ 480 nm
and lemission in the range 500–750 nm using a Hitachi F 2500
spectrouorometer.

2.6

Uptake of MMNs by HeLa cells was studied using confocal
microscopy. MMNs were labelled with a positively charged
uorescent dye, rhodamine-6G by incubating MMNs (2 mg
mL1 in PBS, pH 7.4) with rhodamine-6G (1 mg mL1) with
constant shaking for 12 h at room temperature. HeLa cells were
plated on coverslips at a density of 1  105 cells per well in a 12well plate. Aer 24 h, the cells were incubated with 0.1 mg mL1
rhodamine-labeled MMNs for 4 and 24 h. The cells were washed
3 times with PBS (pH 7.4), xed with 4% paraformaldehyde,
mounted on a glass slide and then examined with an IX81
FV500 laser scanning confocal microscope (Olympus, Tokyo,
Japan). The images were digitally magnied 6 times using
FluoView soware (Olympus, Tokyo, Japan).
2.7

Cell culture

The cell culture experiments were carried out with L929 and
HeLa cell lines. L929 cells were grown in DMEM medium
(Himedia Laboratories Pvt Ltd, Mumbai, India) and HeLa cells
were grown in DMEM medium supplemented with 10% fetal
bovine serum and an antibiotic–antimycotic mix (Himedia
Laboratories Pvt Ltd, Mumbai, India) at 37  C in a humidied
and 5% CO2 atmosphere (InCu-safe).
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In vitro biocompatibility of MMNs

The biocompatibility of MMNs was evaluated for L929 cells by
using an MTS proliferation assay kit (Promega). For cytotoxicity
assays, L929 cells were cultured (2  104 cells per well) in 96well plates for 24 h. Aer incubation, the old media was
replaced by fresh media containing bare MMNs in the
concentration range 0.05 to 0.6 mg mL1 and again incubated
for another 24 and 48 h. Aer incubation, the old media was
removed and 20 mL of MTS/PMS solution in 100 mL of DMEM
media was added to each well. The plate was then incubated for
3 h and the absorbance at 490 nm was measured using a micro
plate reader (Perkin Elmer 1420). The formazan dye generated
by the live cells was proportional to the number of live cells.
Cells without nanoparticles were considered as a control. The
results were quantied by manually subtracting the blank value
from each value then normalizing against the control.
2.8

In vitro antitumour eﬃcacy of DOX–MMNs

HeLa cells were used to examine the in vitro antitumour eﬃcacy
of DOX–MMNs. Briey, 2  104 cells per well were seeded in 96well plate. Aer incubation for 24 h, diﬀerent concentrations of
DOX–MMNs (10 to 120 mg mL1) were added in ve replicates.
HeLa cells cultured in the absence of DOX–MMNs acted as
controls. Aer being cultured for 24 and 48 h, the viability of the
HeLa cells was determined using the MTS assay as described
above. The IC50 values of the DOX–MMNs were expressed as the
free DOX concentrations (1 to 7 mg mL1). The results were
quantied by subtracting the blank value from each value and
then normalizing against the control.
2.9

2.5

Rhodamine-6G–MMNs uptake by HeLa cells

Subcellular localization study of DOX–MMNs

1  105 HeLa cells were seeded on a coverslip. Aer 24 h, the
cells were treated with 0.1 mg mL1 DOX–MMNs for 4 h followed by incubation for 30 min with 1 mM of Lysotracker Red
DND-99 (Invitrogen). The cells were then xed in 4% paraformaldehyde, and the nuclei were stained with DAPI (Calbiochem) for 10 min. Three-channel, optical images (DAPI, DOX,
and Lysotracker Red) were collected using the sequential
scanning mode (405, 480, and 543 nm excitation; 450, 560, and
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595 nm emission) of an IX81 FV500 laser scanning confocal
microscope (Olympus, Tokyo, Japan).
2.10

Cell morphological assessment of apoptosis

To detect morphological evidence of apoptosis, the cell nuclei
were visualized following DNA staining with the uorescent
nuclear dye, ethidium bromide (EtBr). Briey, cells were seeded
at a concentration of 1  105 cells per well on the coverslip in
12-well tissue culture plates and treated with DOX–MMNs
(0.1 mg of MMNs per mL, 20 mg equivalent DOX per mL) for 4,
24 and 48 h. At the end of the incubation, the cells were washed
thoroughly with PBS, xed with 70% ethanol and incubated
with EtBr (12 mM) for 10 min. The cells were again washed with
PBS, mounted on a glass slide and then examined with an IX81
FV500 laser scanning confocal microscope.
2.11

tetramethylrhodamine-B-isothiocyanate and the nucleus by 4,6diamidino-2-phenylindole (DAPI) according to the protocol of
Sigma-Aldrich. 3-(4,5-Dimethyl-thiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) as well as a live/dead assay were used for
cell viability studies. For the MTT assay, the cell culture supernatant was replaced with 100 mL of fresh medium containing
10 mL of 5 mg mL1 MTT. The plates were then incubated for 4 h
at 37  C. The purple formazan crystals were dissolved in 50%
DMF in a water solution containing 5% SDS (sodium dodecyl
sulfate). Thereaer, the absorbance was measured at a wavelength of 550 nm in a plate reader.
The cell viability percentage was calculated using the
following equation:
Cell viability ¼
Absorbance of the treated well with MMNs
 100
Absorbance of control

In vitro magnetic hyperthermia experiments

The heating ability of the MMN suspension in PBS was obtained
from time dependent calorimetric measurements using an
induction heating unit (Comdel CLF-5000, Ameritherm) operating at frequency of 425 kHz. In brief, 0.5 mg of MMNs per mL
(approximate metal ion concentration) in PBS was subjected to
AC magnetic elds (AMFs) of 7 kA m1 and 10 kA m1, at a
frequency of 425 kHz, to evaluate the specic absorption rate
(SAR). The SAR was calculated using the following equation:
SAR ¼ C

DT 1
Dt mFe

(3)

where C is the specic heat of the solvent (Cwater ¼ 4.18 J g1  C),
DT/Dt is the initial slope of the time-dependent temperature
curve and mFe is the mass fraction of Fe in PBS.
For the in vitro magnetic hyperthermia treatment (MHT)
experiments, HeLa cells were grown up to 90% conuency in a
25 cm2 culture ask. The culture medium was replaced with
2 mL of PEGylated MMNs dispersed in DMEM media at a
concentration of 0.5 mg of MMNs per mL. Aer 24 h, the DMEM
medium was removed and the cell layer was washed three times
with PBS, detached from the substratum and pelleted by
centrifugation. The cellular pellet was then transferred to a
2 mL Teon sample vial, yielding concentrations of 2  106
HeLa cells per 1 mL of PBS. The cells were nally exposed to a
magnetic hyperthermia setup, by applying an alternating
magnetic eld at a frequency of 425 kHz and at a magnetic eld
amplitude of 7 kA m1 for 5 min to raise the temperature to 43–
45  C. The same procedure was also performed for DOX–MMNs
to evaluate their combined eﬀect for cancer cell death. For a
comparative study, HeLa cells were treated using MHT alone
(without MMNs and DOX) and, DOX–MMNs (0.5 mg mL1,
20 mg equivalent DOX per mL) with and without MHT. Cells
without any treatment were used as a control. Aer the thermal
treatment, the HeLa cells were centrifuged and settled with a
magnet. The cell pellet was washed three times with PBS. Then,
100 mL of a 2  106 cells per mL solution was seeded in 96 well
plates in 16 replicates, followed by incubation for 24 h in a 5%
CO2 incubator. The morphological features of the treated cells
were observed by actin staining with phalloidin-
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(4)

For the live/dead assay, the treated cells were stained with
calcein AM (2 mM) and ethidium homodimer-1 (4 mM) for
30 min. The cells were observed using an IX81 FV500 laser
scanning confocal microscope (Olympus, Tokyo, Japan).

3

Results and discussion

3.1

Structural characterization of MMNs

The microstructure and surface morphology of the as-synthesized MMNs were observed by SEM (Fig. 1a and b) and TEM (see
ESI, Fig. S1a–c†). The microstructures show that the particles are
spherical and porous. The submicron sized (>250 nm) nanoassemblies were formed in the absence of an external reducing
agent but a reduction in the size of nanoassemblies (<100 nm)
was obtained in the presence of an extra reducing agent, sodium
borohydride (NaBH4). The addition of a strong reducing agent
during the reaction initiated a super saturation state that led to
the formation of a large number of nuclei and subsequent
assembling resulted in the evolution of smaller MMNs.20 The
XRD pattern of the MMNs shows a typical face centered cubic
inverse spinel structure (Fig. S2a†). The crystallite size estimated
from the peak broadening corresponding to the (311) plane
using the Debye–Scherrer equation was found to be 11.5 nm.
A lattice parameter of 8.32 Å and a unit cell volume of 577 Å3
were obtained. A comparison of the crystallite size (estimated
from XRD) and the cluster size from high resolution TEM images
indicates that the MMNs consisted of an assembly of individual

Fig. 1 SEM images of PEGylated MMNs synthesized (a) without and (b) with
NaBH4 (0.05 g). The inset shows the TEM image of a single MMN.
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particles with sizes of less than 12 nm. EDX analysis conrms the
composition of the MMNs (Fig. S2b†). The formation mechanism of the MMNs can be described as a two stage reaction. The
nucleation of nanocrystals occurs in the primary stage of the
reaction in a supersaturated solution followed by aggregation
into larger aggregates or secondary particles.12,21 The number
density of the particles as well as the relative strength of the
anisotropic dipole–dipole and isotropic van der Waals coupling
also inuence the above mechanism.22 The nitrogen (N2)
adsorption–desorption isotherm shows a pore size distribution
having intrapores (3 nm) and interpores (30 nm) and a
specic surface area of 92 cm2 g1 (Fig. 2a). The mesoporous
nature, size of below 100 nm and large specic surface area make
MMNs ideal nanocarriers for drug delivery applications. The
Fourier-transform infrared (FTIR) spectrum (Fig. 2b) of PEGylated MMNs shows the presence of bands at 1107 and 1402 cm-1
which are due to the C–O–C ether stretching vibration of HOOC–
PEG–COOH with bands shied compared to those of the free
PEG molecule indicating its attachment on the MMNs.23
The bands at 1608 and 3400 cm1 are due to the O–H
bending and stretching frequencies of the carboxylate group
which are diﬀerent and at a lower wavenumber than the free
O–H group indicating the presence of a hydrogen bond in the
EG molecule and its attachment on the surface of the MMNs.23
The thermogravimetry (TG) analysis (Fig. S3a†) shows the
sequential weight loss in diﬀerent temperature ranges due to
the loss of physically adsorbed and chemically bonded water
molecules and the decomposition of organic carbonaceous
materials to form CO2 gas. The TG analysis along with the FTIR
data conrms the attachment of PEG-diacid on the MMNs.
Furthermore, the zeta potential of the MMNs was determined
and found to be 23.6 mV. The coating of PEG-diacid
enables a good colloidal stability of the MMNs in PBS, which is
necessary for their use in drug delivery applications (Fig. S3b†).
The M–H curve (Fig. S4†) shows a typical superparamagnetic
nature of the MMNs with magnetization of 57 emu g1
measured in a eld of 2 Tesla. The blocking temperature (Tb)
was found to be 100 K from the zero eld cool and eld cool
(ZFC–FC) curve. The higher magnetic moment and superparamagnetic nature of the MMNs are the required attributes
for magnetic hyperthermia (MHT).

Fig. 2 (a) N2 adsorption–desorption isotherms and pore size distribution (inset)
of as-synthesized MMNs. (b) FT-IR spectra of the (i) PEG-diacid coated MMNs and
(ii) bare PEG-diacid.
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3.2

In vitro and intracellular DOX release

We have further demonstrated the interaction and cellular
uptake of rhodamine-6G (lex ¼ 530 nm, lem ¼ 555 nm) labelled
MMNs by cancer cells. Fig. 3i–iii shows the appearance of
granulated red uorescence aer incubation for 4 h, which
indicates the uptake of MMNs by the HeLa cells. The higher
uptake of MMNs may be attributed due to the PEG coating,
which retards the adsorption of unwanted biomolecules on the
surface.16
The biocompatibility of MMNs was studied on mouse
broblast cells (L929) by MTS assay. We observed no signicant
cytotoxicity eﬀect of the MMNs on the cells at concentrations of
up to 0.4 mg of MMNs per mL (in terms of the metal ion
concentration) aer 24 and 48 h of incubation (Fig. S5a and b†).
Microscopic images show that up to 0.2 mg of MMNs per mL,
the growth and morphology of the L929 cells are similar to cells
incubated in media without MMNs (control) at the corresponding time intervals. However, at a concentration of 0.6 mg
of MMNs per mL, a slight shrinkage of the cells was observed
without aﬀecting the viability of the cells. The cationic DOX was
used as a model anticancer drug for loading and release studies
of the MMNs. The DOX was loaded through electrostatic
interaction with the negatively charged carboxyl enriched
MMNs in PBS medium (pH ¼ 7.4) by mixing for 24 h. The
uorescence intensity of supernatant liquid was recorded aer
magnetic separation of DOX-bound MMNs. The uorescence
intensity of the free DOX (16 mg in 600 mL of PBS) quantied by
UV-vis absorbance with a prominent DOX peak at 490 nm,
decreased upon the addition of diﬀerent amounts of MMNs
(Fig. 4a). This is obvious due to the quenching of the DOX
uorescence upon interaction with the MMNs. 80% (w/w) drug
loading was achieved under physiological conditions (pH 7.4) in
which the daunosamine group of DOX was deprotonated and its
solubility in water decreased.24 The large amount of DOX
loading could possibly be due to the high specic surface area,
negative charge and mesoporous nature of the MMNs.
Next, we investigated the release prole of DOX at diﬀerent
physiological pH values. A higher release (75–80%) was
observed at a lower pH (5.2) as compared to 20–25% at a higher
pH (7.4) within 24 h (Fig. 4b). The high release of DOX in a mild
acidic environment might be due to the dissolution of PEG and
weakening of electrostatic bonding by excessive deprotonation
of the daunosamine group of the DOX.6,23 This is favourable for

Fig. 3 Cellular uptake behaviour of rhodamine-6G labelled MMNs by HeLa cells
after incubation for 4 h: confocal image of (i) rhodamine-6G labeled MMNs, (ii)
diﬀerential interference contrast (DIC) image, (iii) overlay image of (i) and (ii)
showing red granulated ﬂuorescence which conﬁrms the presence of MMNs
inside the cancer cells.
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Fig. 4 (a) Fluorescence spectra of DOX solution (16 mg in 600 mL of PBS, pH 7.4)
with diﬀerent concentrations of MMNs (in terms of the metal concentration) for
the preparation of DOX–MMNs and (b) release proﬁle of DOX from MMN solution
at pH 5.2 and pH 7.4. The measurements were made at 37  C.

the eﬀective treatment of cancer because the majority of
tumours have mildly acidic cellular environments.24,25 Additionally, the mesoporous nature of the MMNs protects the drug
payload from unwanted enzymatic degradation and protein biofouling which usually happens with free DOX in blood.24
Next, we tested the antitumour ability of DOX–MMNs on HeLa
cells. The temporal concentration response of the DOX–MMN
conjugates was monitored by the MTS assay (Fig. S6a and b†).
The IC50 values for the conjugate were found to be 3.5 and 1 mg of
DOX per mL at 24 and 48 h, respectively. Having established an
antitumour activity of the DOX–MMN conjugates, we studied in
vitro DOX release by the conjugates in HeLa cancer cells,
observed through confocal uorescence imaging (Fig. 5a and b).
The morphology of the HeLa cells was observed by incubating
them with the conjugates (0.1 mg of MMNs per mL, 20 mg
equivalent DOX per mL) for 4, 24 and 48 h (Fig. 5b-v–vii) and the
results were compared with the free DOX (20 mg mL1) treated
cells (Fig. 5b-ii–iv). Cells cultured under the same conditions
without DOX–MMNs incubation were used as a control (Fig. 5bi). Aer entering into the cells, the DOX was released from the
conjugates in a mildly acidic environment of late endosomes/
lysosomes (pH 4.7) due to deprotonation of the daunosamine
group of DOX (Fig. 5a). Lysotracker red was used to stain the
DOX–MMNs encapsulated lysosomes, which is more evident due
to the appearance of an orange colour due to the overlay of green
(DOX) and red (lysotracker) orescence as shown in (Fig. 5a-i–iv).
Aer uptake for 4 h, DOX started to diﬀuse from the cellular
compartment to the nuclear compartment. Several reports show
that DOX directly intercalates with DNA or DNA topoisomerase II
and inhibits RNA synthesis to elicit its cytotoxic eﬀect.25,26
Interestingly, we observed a good relationship between the
antitumour activity of the DOX–MMNs and the stimulation of
apoptosis. The apoptotic nuclei were observed by staining them
with a nuclear dye ethidium bromide that gave red uorescence
when excited at 518 nm. The DOX–MMNs gave green uorescence due to the presence of DOX. Fig. 5b-i shows that cells from
the control group exhibited evenly stained nuclei and intact
nuclear membranes showing 99% cell viability. In contrast to
this, Fig. 5b-ii–iv (DOX alone) and Fig. 5b-v–vii (DOX–MMN
conjugates) show loss of cell membrane integrity, complete DNA
fragmentation and a reduction in the size of the nucleus. These
are the most prominent morphological markers used for the
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Fig. 5 (a) Subcellular localization of DOX–MMNs in HeLa cells after incubation for
4 h: (a-i) DOX–MMNs (ﬂuorescence of DOX, green color), (a-ii) lysosomal compartment of cells (lysotracker dye, red), (a-iii) nucleus stained with DAPI (4,6-diamidino2-phenylindole, blue color), (a-iv) merged image of DOX–MMNs and lysotracker
signals (orange colour) suggest localization of DOX–MMNs in the lysosomal
compartment (pH 5) of the cell. (b) In vitro eﬃcacy of DOX–MMNs for the delivery of
DOX in cancer cells. Confocal laser scanning microscopy (CLSM) images show the
apoptosis (DNA fragmentation) in HeLa cells. (i) Control (without DOX) showing
rounded, intact nucleus; (ii–iv) with DOX (20 mg mL1) alone and (v–vii) with DOX–
MMN conjugates (0.5 mg of MMNs per mL in terms of the metal ion concentration
with 20 mg equivalent DOX per mL) at indicated time intervals of 4, 24, and 48 h at
37  C, without any heat treatment. The green ﬂuorescence shows DOX–MMNs, red
ﬂuorescence shows ethidium bromide (EtBr) stained nuclei. The scale bar is 50 mm.
Enlarged images show typical apoptotic nuclei with fragmented morphology.

identication of apoptosis in cancer cells and represent important events in successful chemotherapeutic treatment from
which a cancer cell cannot return to a live condition. Gao et al.
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have demonstrated the same approach of apoptosis induction in
MCF-7 and drug-resistant MCF-7/ADR breast cancer cells using
DOX released from mesoporous silica nanoparticles.25 Likewise,
Li and co-workers reported DNA fragmentation as a major event
in the apoptosis of HeLa cells using DOX loaded dextran nanoparticles.26 Our results show that DOX–MMN conjugates have
toxic eﬀects comparable to those of the free DOX, although free
DOX induces more cell death. The free DOX enters into the
cytoplasm of the cancer cells through passive diﬀusion but is
easily eﬄuxed by the P-glycoprotein eﬄux pump, active in all
types of tumour,25,27 whereas DOX–MMN conjugates are internalized via endocytosis.24,25 Drug eﬄux by the cancer cell is a
major hurdle for eﬀective chemotherapeutic treatment. These
conjugates not only have the capability to reduce the toxicity of
free DOX but also help in enhancing the therapeutic eﬃcacy of
DOX by reducing the drug eﬄux problem and increasing the
DOX retention time inside cancer cells.

3.3

In vitro chemo-thermal evaluation of DOX–MMNs

Previous studies have reported the extensive use of MgFe2O4
nanoparticles for magnetic hyperthermia.28,29 In order to use
DOX–MMNs for chemo-thermal therapy, the heating eﬃciency
of MMNs was evaluated under an AMF with a frequency of
425 kHz and strengths of 7 and 10 kA m1 s1 (Fig. 6a). The
temperature of the solution containing 0.5 mg of MMNs per mL
of PBS increased to 42–43  C within 5 minutes. This temperature
is recommended as the therapeutic threshold temperature
required for hyperthermia. We found a variation of the SAR value
at the two diﬀerent eld strengths, 7 kA m1 s1 (95.38 W per g of
Fe) and 10 kA m1 s1 (153.4 W per g of Fe) at a xed frequency of
425 kHz. This is obvious because the SAR value increased proportionally to the eld strength and frequency.9,30
Next, we investigated the rationale behind the hyperthermia
induced enhancement of the DOX toxicity. The bare MMNs and
DOX–MMN conjugates (20 mg equivalent DOX per mL) at
concentrations of 0.5 mg of MMNs per mL were incubated for 24 h
with cancer cells. The cells without MMNs and DOX treatment
were used as a control. Aer incubation for 24 h, the cells (2  106
cells per pellet) were subjected to an AMF of 7 kA m1 s1 at a
frequency of 425 kHz for 5 minutes to evaluate the individual and
combined eﬀect of bare MMNs and DOX–MMN conjugates on the
proliferation of cancer cells. Following magnetic hyperthermia
treatment, the cells were washed with PBS and allowed to grow for
24 h. The morphology of the control and MHT treated cells were
observed by DIC and confocal imaging (Fig. 6bi–iv). The actin
laments were stained with phalloidin-tetramethylrhodamine-Bisothiocyanate and the nucleus with 4,6-diamidino-2-phenylindole dye (DAPI). The confocal images show plasma membrane
distortion, blebbing, disorganization of the cytoskeleton protein
(F-actin) and shrinkage of the nucleus upon treatment, a prominent marker of hyperthermia induced late apoptosis in cancer
cells (Fig. 6ii and iv). Thomas et al. also found a similar apoptosis
phenomenon when breast cancer cells (MDA-MB-231) were subjected to MHT with magnetic core silica nanoparticles (MCSNs).4
A similar approach was attempted by Prasad et al. using gMnxFe2xO3 for the hyperthermia treatment of cancer cells.31
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Fig. 6 (a) Temperature vs. time plots of PEGylated MMNs (5 mL, 0.5 mg of MMNs
per mL in PBS in terms of the metal concentration) under AC magnetic ﬁelds of
diﬀerent strengths. (b) In vitro hyperthermia (MHT) study of MMNs alone with
HeLa cells under an AC magnetic ﬁeld (AMF) of 425 kHz, 7 kA m1 for 5 minutes
at 43–45  C: (b-i) diﬀerential interference contrast (DIC) image, (b-ii) confocal
image of control HeLa cells stained with phalloidin-tetramethylrhodamine-Bisothiocyanate (red) for actin ﬁlaments and 4,6-diamidino-2-phenylindole dye
(DAPI, blue color) for the nucleus, (b-iii and iv) DIC and confocal images of MHT
treated HeLa cells showing the blebbing formation and distortion of the cell
membrane, a morphological indication of cell late apoptosis/necrosis.

The live/dead assay was performed for a qualitative assessment of the dual therapy eﬀect on the viability of cancer cells
(Fig. 7a). A quantitative estimation of cell viability was achieved
using the MTT assay (Fig. 7b). Both the live/dead and MTT assay
demonstrated a signicant increase in toxicity of the DOX–
MMNs, when combined with MHT (Fig. 7a and b). It was
observed that cells treated with MMNs and exposed to MHT
showed 45% cell death while cells treated with DOX–MMN
conjugates (20 mg equivalent DOX per mL) without MHT
exhibited 65% cell death. However, cells simultaneously treated
with DOX–MMN conjugates (20 mg equivalent DOX per mL)
and MHT resulted in cell death of up to 90%. Our results are
consistent with the ndings of Brule et al., which demonstrated
the combined eﬀect of chemo-thermal therapy on cancer cells
using magnetic alginate microspheres. Their study showed that
the combination of a drug and magnetic hyperthermia induces
more cell death as compared to the eﬀects of individual
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Conclusions

In summary, biocompatible and biodegradable PEG coated
carboxyl-enriched MgFe2O4 MMNs with sizes less than 100 nm
have been developed to evaluate the synergistic eﬀect of chemothermal therapy in vitro. The negatively charged, mesoporous
MMNs help in terms of a high loading eﬃciency and pH
induced DOX release for cancer cell death. Hyperthermia
signicantly enhances the therapeutic eﬃcacy of DOX, leading
to more cell death in comparison to the individual treatments of
hyperthermia or DOX. This study suggests that MMNs act as a
novel therapeutic mediator, having the potential to reduce the
toxicity of DOX and increase its aqueous solubility with two
therapeutic modalities, chemo- and thermal therapy in a single
system, for the eﬀective treatment of cancer. Further studies are
ongoing for the development of DOX–MMN conjugation
through acid labile hydrazone bonds and their implication in
bimodal drug delivery and MR imaging. Additionally, the role of
Mg2+ ions in the apoptosis of cancer cells is under examination.
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Fig. 7 (a) Live/dead assay for the synergistic eﬀect of chemo-thermal therapy in
vitro: cells were stained with calcein (green) and ethidium homodimer-1 (red) for
the visualization of live and dead cells, respectively. (b) Cells were treated with
free DOX (20 mg mL1), MMNs, and DOX–MMN conjugates (20 mg equivalent
DOX per mL). The cells without DOX and MMN incubation were used as a control.
Quantitative evaluation of cell viability was determined using the MTT assay. The
DOX–MMN eﬃcacy was signiﬁcantly enhanced when combined with hyperthermia (MHT), almost 90% of cancer cells died. The viability of the control cells or
DOX incubated cells was not eﬀected by hyperthermia. Data shown are means 
SD from n ¼ 3. **P < 0.01.

therapy.3 A similar result was reported by Lee et al. in their study
with lung cancer cells in which they showed that hyperthermia
improves the eﬃcacy of chemotherapy using mesoporous silica
nanoparticles.32 On similar lines, the present study also
suggests that the combination of chemo-thermal therapy
induces the destruction of HeLa cancer cells more eﬃciently
than the individual eﬀect of DOX or MHT treatment alone. Noh
et al. even reported the signicance of the dual therapy by
inducing more cell death in the drug resistant cancer cell line
DLD-1-ADR vs. normal cancer cells.33 With the same views as in
the studies by Noh et al., it is predicted that the problem of drug
resistant cancer cells and drug eﬄux, a major hurdle in the
treatment of cancer, can be solved by the application of chemothermal therapy. With these features, MMNs appear to be a
potential integrated nanoparticles system combining magnetic
hyperthermia with drug delivery for eﬀective cancer therapy.

This journal is ª The Royal Society of Chemistry 2013

Notes and references
1 R. A. Petros and J. M. Desimone, Nat. Rev. Drug Discovery,
2010, 9, 615–627.
2 S. Chandra, K. C. Barick and D. Bahadur, Adv. Drug Delivery
Rev., 2011, 63, 1267–1281.
3 S. Brule, M. Levy, C. Wilhelm, D. Letourneur, F. Gazeau,
C. Menager and C. L. Visage, Adv. Mater., 2011, 23, 787–790.
4 C. R. Thomas, D. P. Ferris, J. H. Lee, E. Choi, M. H. Cho,
E. S. Kim, J. F. Stoddart, J. S. Shin, J. Cheon and J. I. Zink,
J. Am. Chem. Soc., 2010, 132, 10623–10625.
5 J. You, R. Zhang, G. Zhang, M. Zhong, Y. Liu, C. S. V. Pelt,
D. Liang, W. Wei, A. K. Sood and C. Li, ACS Nano, 2012,
158, 319–328.
6 S. P. Sherlock, S. M. Tabakman, L. Xie and H. Die, ACS Nano,
2011, 5, 1505–1512.
7 K. Yang, S. Zhang, G. Zhang, X. Sun, S. T. Lee and Z. Liu,
Nano Lett., 2010, 10, 3318–3323.
8 P. Pradhan, J. Giri, F. Rieken, C. Koch, O. Mykhaylyk,
M. Doblinger, D. Bahadur and C. Plank, J. Controlled
Release, 2010, 142, 108–121.
9 K. C. Barick, M. Aslam, Y. P. Lin, D. Bahadur, P. V. Prasad
and V. P. Dravid, J. Mater. Chem., 2009, 19, 7023–7029.
10 J. T. Jang, H. Nah, J. H. Lee, S. H. Lee, S. H. Moon, M. G. Kim
and J. Cheon, Angew. Chem., Int. Ed., 2009, 48, 1234–
1238.
11 K. C. Barick, S. Singh, N. V. Jadhav, D. Bahadur, B. N. Pandey
and P. A. Hassan, Adv. Funct. Mater., 2012, 22, 4975–4984.

J. Mater. Chem. B, 2013, 1, 3652–3660 | 3659

View Article Online

Journal of Materials Chemistry B
12 B. Luo, S. Xu, A. Luo, W. R. Wang, S. L. Wang, J. Guo, Y. Lin,
D. Zhao and C. C. Wang, ACS Nano, 2011, 5, 1428–
1435.
13 B. Luo, S. Xu, W. F. Ma, W. R. Wang, S. L. Wang, J. Guo,
W. L. Yang, J. H. Hu and C. C. Wang, J. Mater. Chem.,
2010, 20, 7107–7113.
14 J. Ge, Y. Hu, M. Biasini, W. P. Beyermann and Y. Yin, Angew.
Chem., Int. Ed., 2007, 46, 4342–4345.
15 J. Liu, Z. Sun, Y. Deng, Y. Zou, C. Li, X. Guo, L. Xiong, Y. Gao,
F. Li and D. Zhao, Angew. Chem., Int. Ed., 2009, 48, 5875–
5879.
16 Y. Zhang, N. Kohler and M. Zhang, Biomaterials, 2002, 23,
1553–1561.
17 J. Xie, C. Xu, N. Kohler, Y. Hou and S. Sun, Adv. Mater., 2007,
19, 3163–3166.
18 C. Martinez-Boubeta, L. Balcells, R. Cristòfol, C. Sanfeliu,
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